Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 2Gastrointestinal Neoplasms 1Gastroesophageal Reflux 1Barrett Esophagus 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 765Gemcitabine 651Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 441Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 218pembrolizumab 206Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 181Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × linaclotide × Gastrointestinal × Clear all
NCT05107219 2026-04-07

GCC Agonist Signal in the Small Intestine

University of Wisconsin, Madison

Phase 1 Completed
43 enrolled
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux, Gastrointestinal Neoplasms

NCT03796884 2026-04-02

Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

Thomas Jefferson University

Phase 2 Active not recruiting
230 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01950403 2024-12-09

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

Mayo Clinic

Phase 1 Completed
24 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡